<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the ðŸ”— symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### [Preprints => Peer-Reviewed Publications (Nov 10)](/page/updates/#preprints.peer-reviewed.publications)
4 published preprints were added.
### Database Entries (Nov 09)
Westberg M, Su Y, et int., and Lin MZ. [â€œRational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases.â€](/search/?article=Westberg20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.15.275891](https://doi.org/10.1101/2020.09.15.275891).
### Database Entries (Nov 07)
Chi X, Liu X, et int., and Yang W. [â€œHumanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.â€](/search/?article=Chi20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18387-8](https://doi.org/10.1038/s41467-020-18387-8). \[[PubMed32913273](https://www.ncbi.nlm.nih.gov/pubmed/32913273/)\] \[[PMC7483421](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483421/)\]
### Database Entries (Nov 07)
de Vries RD, Schmitz KS, et int., and Porotto M. [â€œIntranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.â€](/search/?article=deVries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.04.361154](https://doi.org/10.1101/2020.11.04.361154).
### [Preprints => Peer-Reviewed Publications (Nov 7)](/page/updates/#preprints.peer-reviewed.publications)
2 published preprints were added.
### [Clinical Trials (Nov 05)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-05)

### Database Entries (Nov 05)
Bojkova D, Bechtel M, et int., and Cinatl J. [â€œAprotinin Inhibits SARS-CoV-2 Replication.â€](/search/?article=Bojkova20c) _Cells_, 2020. [doi.org/10.3390/cells9112377](https://doi.org/10.3390/cells9112377). \[[PubMed33143316](https://www.ncbi.nlm.nih.gov/pubmed/33143316/)\]
### Database Entries (Nov 05)
Li Y, Cao L, et int., and Zhang X. [â€œRemdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models.â€](/search/?article=Li20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.353300](https://doi.org/10.1101/2020.10.26.353300).
### Database Entries (Nov 04)
Cai Y, Xu W, et int., and Jiang S. [â€œGriffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.â€](/search/?article=Cai20b) _Virologica Sinica_, 2020. [doi.org/10.1007/s12250-020-00305-3](https://doi.org/10.1007/s12250-020-00305-3). \[[PubMed33052520](https://www.ncbi.nlm.nih.gov/pubmed/33052520/)\] \[[PMC7554295](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554295/)\]
### Database Entries (Nov 04)
Weisblum Y, Schmidt F, et int., and Bieniasz PD. [â€œEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants.â€](/search/?article=Weisblum20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214759](https://doi.org/10.1101/2020.07.21.214759). \[[PubMed32743579](https://www.ncbi.nlm.nih.gov/pubmed/32743579/)\] \[[PMC7386497](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386497/)\]
### Database Entries (Nov 04)
Yuan S, Yin X, et int., and Yuen K. [â€œClofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.â€](/search/?article=Yuan20e) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86169/v1](https://doi.org/10.21203/rs.3.rs-86169/v1). \[[PubMed33052331](https://www.ncbi.nlm.nih.gov/pubmed/33052331/)\] \[[PMC7553155](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/)\]
### [Preprints => Peer-Reviewed Publications (Nov 4)](/page/updates/#preprints.peer-reviewed.publications)
1 published preprints were added.
### Database Entries (Nov 03)
Bakovic A, Risner K, et int., and Narayanan A. [â€œBrilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.â€](/search/?article=Bakovic20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.29.352450](https://doi.org/10.1101/2020.10.29.352450).
### Database Entries (Nov 03)
Chan CE, Seah SG, et int., and Hanson BJ. [â€œThe Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.â€](/search/?article=Chan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.355107](https://doi.org/10.1101/2020.10.26.355107).
### Database Entries (Nov 03)
Fu Y, Maruyama J, et int., and Allen RD. [â€œProtective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.â€](/search/?article=Fu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.28.359836](https://doi.org/10.1101/2020.10.28.359836).
### Database Entries (Nov 03)
Halfon P, Bestion E, et int., and Schinazi RF. [â€œGNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.â€](/search/?article=Halfon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.327635](https://doi.org/10.1101/2020.10.06.327635). \[[PubMed33052342](https://www.ncbi.nlm.nih.gov/pubmed/33052342/)\] \[[PMC7553169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553169/)\]
### Database Entries (Nov 03)
Hashim HA, Maulood MF, et int., and Abdulamir AS. [â€œControlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.â€](/search/?article=Hashim20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.26.20219345](https://doi.org/10.1101/2020.10.26.20219345).
### Database Entries (Nov 03)
Li T, Sun L, et int., and Shen X. [â€œBromhexine Hydrochloride Tablets for the Treatment of Moderate COVIDâ€19: An Openâ€Label Randomized Controlled Pilot Study.â€](/search/?article=Li20f) _Clinical and Translational Science_, 2020. [doi.org/10.1111/cts.12881](https://doi.org/10.1111/cts.12881). \[[PubMed32881359](https://www.ncbi.nlm.nih.gov/pubmed/32881359/)\]
### Database Entries (Nov 03)
Mellott D, Tseng C, et int., and McKerrow JH. [â€œA cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.â€](/search/?article=Mellott20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.23.347534](https://doi.org/10.1101/2020.10.23.347534).
### Database Entries (Nov 03)
Rosenfeld R, Noy-Porat T, et int., and Mazor O. [â€œPost-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.â€](/search/?article=Rosenfeld20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.354811](https://doi.org/10.1101/2020.10.26.354811).
### Database Entries (Nov 03)
Zandi K, Amblard F, et int., and Schinazi RF. [â€œRepurposing Nucleoside Analogs for Human Coronaviruses.â€](/search/?article=Zandi20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01652-20](https://doi.org/10.1128/aac.01652-20). \[[PubMed33122172](https://www.ncbi.nlm.nih.gov/pubmed/33122172/)\]

### [Preprints => Peer-Reviewed Publications (Nov 3)](/page/updates/#preprints.peer-reviewed.publications)

2 published preprints were added.

### Database Entries (Nov 02)
Cao X, Maruyama J, et int., and Allen RD. [â€œDiscovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.â€](/search/?article=Cao20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.27.316174](https://doi.org/10.1101/2020.09.27.316174).

### [Press Release (Oct 30)](/page/updates/#press.release)
[Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201030.pdf)

### [Clinical Trials (Oct 29)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-29)

### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [â€œSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.â€](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]
### [Press Release (Oct 28)](/page/updates/#press.release)
[Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201028.pdf)

### [Press Release (Oct 26)](/page/updates/#press.release)

[Lilly Statement Regarding NIHâ€™s ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [â€œRepurposed antiviral drugs for COVID-19 â€“interim WHO SOLIDARITY trial results.â€](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [â€œEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.â€](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).

### [Clinical Trials (Oct 22)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-22)
### Database Entries (Oct 22)
Rosenke K, Leventhal S, et int., and Stein DA. [â€œInhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers.â€](/search/?article=Rosenke20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.29.319731](https://doi.org/10.1101/2020.09.29.319731). \[[PubMed33024974](https://www.ncbi.nlm.nih.gov/pubmed/33024974/)\] \[[PMC7536879](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536879/)\]
### Database Entries (Oct 22)
Yin W, Luan X, et int., and Xu HE. [â€œStructural basis for repurposing a 100-years-old drug suramin for treating COVID-19.â€](/search/?article=yin20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.328336](https://doi.org/10.1101/2020.10.06.328336).

### [Press Release (Oct 16)](/page/updates/#press.release)
- [IFN Lambda EigerBioPharmaceuticals](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Eiger20201017.pdf)

### [Clinical Trials (Oct 15)](/page/updates/#clinical.trials)
[5 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-15)


### Database Entries (Oct 13)
Olaleye OA, Kaur M, and Onyenaka CC. [â€œAmbroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Proteinâ€™s Receptor Binding Domain and Recombinant Human ACE2.â€](/search/?article=Olaleye20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.13.295691](https://doi.org/10.1101/2020.09.13.295691). \[[PubMed32995775](https://www.ncbi.nlm.nih.gov/pubmed/32995775/)\] \[[PMC7523101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523101/)\]

### Database Entries (Oct 13)
Kaptein SJF, Jacobs S, et int., and Delang L. [â€œFavipiravir at high doses has potent antiviral activity in SARS-CoV-2âˆ’infected hamsters, whereas hydroxychloroquine lacks activity.â€](/search/?article=Kaptein20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2014441117](https://doi.org/10.1073/pnas.2014441117). \[[PubMed33037151](https://www.ncbi.nlm.nih.gov/pubmed/33037151/)\]

### Database Entries (Oct 12)
Arabi YM, Asiri AY, et int., and Alothman A. [â€œInterferon Beta-1b and Lopinavirâ€“Ritonavir for Middle East Respiratory Syndrome.â€](/search/?article=Arabi20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2015294](https://doi.org/10.1056/nejmoa2015294). \[[PubMed33026741](https://www.ncbi.nlm.nih.gov/pubmed/33026741/)\]
### Database Entries (Oct 12)
Beigel JH, Tomashek KM, et int., and Lane HC. [â€œRemdesivir for the Treatment of Covid-19 â€” Final Report.â€](/search/?article=Beigel20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
### Database Entries (Oct 12)
Cho J, Lee YJ, et int., and Choi J. [â€œAntiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.â€](/search/?article=Cho20) _SREP_, 2020. [doi.org/10.1038/s41598-020-72879-7](https://doi.org/10.1038/s41598-020-72879-7). \[[PubMed33004837](https://www.ncbi.nlm.nih.gov/pubmed/33004837/)\] \[[PMC7530981](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530981/)\]
### Database Entries (Oct 12)
Gilmore K, Zhou Y, et int., and Seeberger PH. [â€œIn vitro efficacy of Artemisinin-based treatments against SARS-CoV-2.â€](/search/?article=Gilmore20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.05.326637](https://doi.org/10.1101/2020.10.05.326637).
### [Preprints => Peer-Reviewed Publications (Oct 12)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.
